Findings from the Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group: The power of pooled individual patient data from multiple clinical trials

Lindsay A. Renfro, Daniel J. Sargent

Research output: Contribution to journalArticle

Abstract

The Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group was formed 15 years ago to address scientific questions in early stage colon cancer that could best be answered by pooling individual patient data across many randomized clinical trials. Today, the ACCENT database contains detailed information collected from over 40,000 patients enrolled onto 27 major adjuvant colon cancer trials conducted between 1977 and 2009. Since its inception, the ACCENT group has led many sophisticated analyses addressing a variety of clinical questions, such as the long-term survivorship of colon cancer patients by treatment, the time course of oxaliplatin benefit, and support for the use of disease-free survival (DFS) as a surrogate endpoint for overall survival (OS), among many others. Here, we provide an updated overview of recent important results and future directions of the ACCENT collaboration.

Original languageEnglish (US)
Article number80
JournalChinese Clinical Oncology
Volume5
Issue number6
DOIs
StatePublished - 2016

Fingerprint

Colonic Neoplasms
Clinical Trials
oxaliplatin
Disease-Free Survival
Survival Rate
Randomized Controlled Trials
Biomarkers
Databases
Survival

Keywords

  • Adjuvant Colon Cancer End Points (ACCENT)
  • Adjuvant treatment
  • Colon cancer
  • Disease-free survival (DFS)
  • FOLFOX
  • Individual patient data
  • Meta-analysis
  • Overall survival (OS)
  • Oxaliplatin
  • Population survival; recurrence; surrogate endpoints

ASJC Scopus subject areas

  • Oncology
  • Medicine(all)

Cite this

Findings from the Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group : The power of pooled individual patient data from multiple clinical trials. / Renfro, Lindsay A.; Sargent, Daniel J.

In: Chinese Clinical Oncology, Vol. 5, No. 6, 80, 2016.

Research output: Contribution to journalArticle

@article{3e38bf60b7e8405f9f0a55749fe02b95,
title = "Findings from the Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group: The power of pooled individual patient data from multiple clinical trials",
abstract = "The Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group was formed 15 years ago to address scientific questions in early stage colon cancer that could best be answered by pooling individual patient data across many randomized clinical trials. Today, the ACCENT database contains detailed information collected from over 40,000 patients enrolled onto 27 major adjuvant colon cancer trials conducted between 1977 and 2009. Since its inception, the ACCENT group has led many sophisticated analyses addressing a variety of clinical questions, such as the long-term survivorship of colon cancer patients by treatment, the time course of oxaliplatin benefit, and support for the use of disease-free survival (DFS) as a surrogate endpoint for overall survival (OS), among many others. Here, we provide an updated overview of recent important results and future directions of the ACCENT collaboration.",
keywords = "Adjuvant Colon Cancer End Points (ACCENT), Adjuvant treatment, Colon cancer, Disease-free survival (DFS), FOLFOX, Individual patient data, Meta-analysis, Overall survival (OS), Oxaliplatin, Population survival; recurrence; surrogate endpoints",
author = "Renfro, {Lindsay A.} and Sargent, {Daniel J.}",
year = "2016",
doi = "10.21037/cco.2016.12.02",
language = "English (US)",
volume = "5",
journal = "Chinese Clinical Oncology",
issn = "2304-3865",
publisher = "Society for Translational Medicine (STM)",
number = "6",

}

TY - JOUR

T1 - Findings from the Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group

T2 - The power of pooled individual patient data from multiple clinical trials

AU - Renfro, Lindsay A.

AU - Sargent, Daniel J.

PY - 2016

Y1 - 2016

N2 - The Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group was formed 15 years ago to address scientific questions in early stage colon cancer that could best be answered by pooling individual patient data across many randomized clinical trials. Today, the ACCENT database contains detailed information collected from over 40,000 patients enrolled onto 27 major adjuvant colon cancer trials conducted between 1977 and 2009. Since its inception, the ACCENT group has led many sophisticated analyses addressing a variety of clinical questions, such as the long-term survivorship of colon cancer patients by treatment, the time course of oxaliplatin benefit, and support for the use of disease-free survival (DFS) as a surrogate endpoint for overall survival (OS), among many others. Here, we provide an updated overview of recent important results and future directions of the ACCENT collaboration.

AB - The Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group was formed 15 years ago to address scientific questions in early stage colon cancer that could best be answered by pooling individual patient data across many randomized clinical trials. Today, the ACCENT database contains detailed information collected from over 40,000 patients enrolled onto 27 major adjuvant colon cancer trials conducted between 1977 and 2009. Since its inception, the ACCENT group has led many sophisticated analyses addressing a variety of clinical questions, such as the long-term survivorship of colon cancer patients by treatment, the time course of oxaliplatin benefit, and support for the use of disease-free survival (DFS) as a surrogate endpoint for overall survival (OS), among many others. Here, we provide an updated overview of recent important results and future directions of the ACCENT collaboration.

KW - Adjuvant Colon Cancer End Points (ACCENT)

KW - Adjuvant treatment

KW - Colon cancer

KW - Disease-free survival (DFS)

KW - FOLFOX

KW - Individual patient data

KW - Meta-analysis

KW - Overall survival (OS)

KW - Oxaliplatin

KW - Population survival; recurrence; surrogate endpoints

UR - http://www.scopus.com/inward/record.url?scp=85010189016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010189016&partnerID=8YFLogxK

U2 - 10.21037/cco.2016.12.02

DO - 10.21037/cco.2016.12.02

M3 - Article

C2 - 28061544

AN - SCOPUS:85010189016

VL - 5

JO - Chinese Clinical Oncology

JF - Chinese Clinical Oncology

SN - 2304-3865

IS - 6

M1 - 80

ER -